Delivery Order SPE2DR25D2206-SPE2DR26F9KF2
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,044.86 to AmerisourceBergen Drug Corp for CABENUVA ER 600 MG-900 MG suspension (6 mL) on December 22, 2025, with completion scheduled for January 14, 2026. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters and primary...
- The Defense Logistics Agency awarded a delivery order valued at $40,224.30 to AmerisourceBergen Drug Corp for CABENUVA ER 600 mg-900 mg suspension (6 mL) on November 13, 2025, with an ultimate completion date of December 5, 2025. This firm fixed price, non-set-aside contract is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency Medical Supply Chain awarded a $38,169 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for CABENUVA ER 600 MG-900 MG Suspension in 6 mL units. This firm fixed-price delivery order, which represents a child contract action under AmerisourceBergen's larger pharmaceutical supply agreements, is scheduled for completion by September 18, 2025, with performance at the company's Conshohocken, Pennsylvania location. The award was competitively awarded with...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $40,921.10 for CABENUVA ER 600 mg-900 mg suspension (6 mL) on January 2, 2026, with an ultimate completion date of January 26, 2026. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a $38,169.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for CABENUVA ER 600 MG-900 MG suspension (6 mL), with an ultimate completion date of May 15, 2025. This non-set-aside competitive award represents a child delivery order against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 27, 2025, for the supply of CABENUVA ER 600 MG-900 MG suspension in 6 mL quantities, valued at $38,169.00 under a firm fixed-price arrangement. This non-competitive set-aside delivery order will be performed in Conshohocken, Pennsylvania, with an ultimate completion date of October 20, 2025. The award represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $38,169.00 to AmerisourceBergen Drug Corp for CABENUVA ER 600 mg–900 mg suspension (6 mL) with a completion date of September 30, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed-price pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 22, 2025, for the supply of Cabenuva ER 600 mg-900 mg suspension (6 mL) with a ceiling value of $40,224.30 and a firm fixed price contract type. This delivery order is non-set-aside and will be completed by January 14, 2026, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $24,134.58 to AmerisourceBergen Drug Corp for CABENUVA ER 600 mg-900 mg suspension (6 mL), a long-acting injectable antiretroviral medication used in HIV treatment. The contract, awarded on November 26, 2025, with an ultimate completion date of December 18, 2025, represents a firm fixed-price delivery order with no set-aside designation. The pharmaceutical product will be delivered to the contractor's facility in Conshohocken,...
- The Defense Logistics Agency awarded a $7,633.80 delivery order to AmerisourceBergen Drug Corp for CABENUVA ER 600 MG-900 MG suspension (6 mL) with a firm fixed price structure and an ultimate completion date of August 20, 2025. This non-set-aside, competitively awarded contract represents a single delivery order executed on July 30, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. CABENUVA is an injectable antiretroviral...
- SPE2DR25D2206Indefinite Delivery Contract
- SPE2DR25D2206-SPE2DR26F9KF2Delivery Order
This delivery order, valued at $40,921.10 and awarded on January 8, 2026, is for CABENUVA ER 600 MG-900 MG suspension (6 mL) supplied by AmerisourceBergen Drug Corp to the Defense Logistics Agency. The award utilizes a firm fixed-price structure with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the awardee operating as a subsidiary of Cencora, Inc., a major pharmaceutical distributor serving federal healthcare systems. The delivery order is expected to be completed by January 30, 2026, with performance at the contractor's Pennsylvania facility. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling supply of a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. The product being delivered—CABENUVA, an antiretroviral medication used in HIV treatment—supports the Department of Defense's medical supply chain requirements for specialty pharmaceuticals across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $40.9k | 1/7/26 |